Table of Contents Adverse Event Reporting SOPs for Medical Devices

Size: px
Start display at page:

Download "Table of Contents Adverse Event Reporting SOPs for Medical Devices"

Transcription

1 Page 2 of 122 Table of Contents Adverse Event Reporting SOPs for Medical Devices Previous Teleconferences About SOPs... 7 Dr. Sharlin's Credentials... 8 Outline Of This Presentation... 9 CDRH Requirements for Written Medical Device Reporting (MDR) Procedures 10 Common Compliance Problems with SOPs Purpose and Benefits of SOPs Summary of SOP Development, Flowchart Summary of SOP Development, Flowchart (2) Summary of SOP Development, Flowchart (3) The Six Most Common Statistical Errors - From CDRH How Reviewers Examine Safety Data How Reviewers Examine Safety Data (2) A Reviewer s Five Sources of Information for a Safety Review Ten Ways To Improve A Submission Using Information From the Reviewer Guidance on Evaluating Safety Data Ten Ways To Improve A Submission Using Information From the Reviewer Guidance on Evaluating Safety Data (2) Overview Flowchart of AE Reporting Before A Medical Device is Approved IDE Regulations

2 Page 3 of 122 Overview of AE Reporting Before A Medical Device is Approved -- PMA Requirements For Safety Data Overview of AE Reporting After A Medical Device is Approved Postmarket Surveillance, 21 CFR Overview of AE Reporting After A Medical Device is Approved Medical Device Reporting (MDR) Voluntary Device Reporting By Health Professionals Voluntary Device Reporting By Health Professionals (2) Mandatory Device Reporting By Health Professionals How FDA Uses MedWatch Data April 2007 Guidance for Clinical Investigators, Sponsors and IRBs; AE Reporting Improving Human Subject Protection (problem statement and participants).. 30 Flowchart of Current AE Reporting Relationships For Drugs & Biologics Flowchart of FDA Recommended AE Reporting Relationships For Drugs & Biologics Flowchart of Current AE Reporting Relationships For Medical Devices Conclusions From April 2007 Guidance for Clinical Investigators, Sponsors and IRBs; AE Reporting Improving Human Subject Protection SOP Format: Section Headings SOP Format: Details How to Change Model SOPs Five Required Activities For Each New SOP Factors That Affect Modification of Model SOPs

3 Page 4 of 122 Six Features of Model SOPs How To Use SOP Deliverables Definitions Applicable to Medical Device Reporting (MDR) Definitions Applicable to Medical Device Reporting (2) Definitions Applicable to Medical Device Reporting (3) Definitions Applicable to Medical Device Reporting (4) Definitions Applicable to Medical Device Reporting (5) Definitions Applicable to Medical Device Reporting (6) Definitions Applicable to Medical Device Reporting (7) Definitions Applicable to Medical Device Reporting (8) Definitions Applicable to Medical Device Reporting (9) Definitions Applicable to Medical Device Reporting (10) Definitions Applicable to Medical Device Reporting (11) Definitions Applicable to Medical Device Reporting (12) Definitions Applicable to Medical Device Reporting (13) Model SOP #1, AE Reporting Before a Device is Approved Model SOP #2, MDR Requirements for Device User Facilities Model SOP #2, MDR Requirements for Device User Facilities (2) Model SOP #2, MDR Requirements for Device User Facilities (3) Model SOP #3, MDR Requirements for Device Importers

4 Page 5 of 122 Model SOP #3, MDR Requirements for Device Importers (2) Model SOP #4, MDR Requirements for Device Manufacturers Model SOP #4, MDR Requirements for Device Manufacturers (2) Model SOP #4, MDR Requirements for Device Manufacturers (3) Model SOP #4, MDR Requirements for Device Manufacturers (4) Model SOP #4, MDR Requirements for Device Manufacturers (5) Model SOP #5, Medical Device Complaint Records Model SOP #5, Medical Device Complaint Records (2) Model SOP #6, Validation of AE Data Capture Systems Model SOP #7, Data Monitoring Committee Model SOP #8, Statistical Analysis of AE Data Model SOP #9, MedDRA Coding of AE Data Summary of Audioconference; Adverse Event Reporting SOPs for Devices Joshua Sharlin, Ph.D., Resume SOP #1, AE Reporting Before a Device is Approved (text) SOP #2, MDR Requirements for Device User Facilities (text) SOP #3, MDR Requirements for Device Importers (text) SOP #4, MDR Requirements for Device Manufacturers (text) SOP #5, Complaint Records (text) SOP #6, Validation of Electronic AE Data Capture Systems (text)

5 Page 6 of 122 SOP #7, Data Monitoring Committee (text) SOP #8, Statistical Analysis of AE Data (text) SOP #9, MedDRA Coding of AE Data (text)

To document the review procedures for a submission regarding compassionate/treatment use of investigational drugs, biologics and devices.

To document the review procedures for a submission regarding compassionate/treatment use of investigational drugs, biologics and devices. UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD COMPASSIONATE/TREATMENT USE OF MEDICAL DRUGS, BIOLOGICS AND DEVICES I. PURPOSE To document the review procedures for a submission

More information

Medidée Services SA. Nano-Tera.ch. 05 February 2015 part 8. PMA, 510k, IDE. Pierre-Alain Sommer

Medidée Services SA. Nano-Tera.ch. 05 February 2015 part 8. PMA, 510k, IDE. Pierre-Alain Sommer Nano-Tera.ch 05 February 2015 part 8 PMA, 510k, IDE Pierre-Alain Sommer Pierre-alain.sommer@medidee.com www.medidee.com Nano-Tera 2015 05.02.2015 USA/FDA Pre Market Approval System - PMA, Pre Market Notifcation

More information

Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration

Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration Kathy.Weil@fda.hhs.gov Follow the protocol and IDE regulations

More information

Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.

Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations. POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: A DF/HCC Investigator who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities that

More information

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities

More information

Teleconference Course Materials You may duplicate this for each person attending the conference.

Teleconference Course Materials You may duplicate this for each person attending the conference. TC001521A & Sharlin Consulting Teleconference Course Materials You may duplicate this for each person attending the conference. Understanding When Clinical Trial Information MUST be Entered Into ClinicalTrials.gov

More information

Prequalification of in vitro diagnostics - Technical Update 24 November 2015

Prequalification of in vitro diagnostics - Technical Update 24 November 2015 Prequalification of in vitro diagnostics - Technical Update 24 November 2015 Copenhagen, Denmark 22-26 November 2015 1 Changes assessment Copenhagen, Denmark 22-26 November 2015 2 Changes to a Prequalified

More information

MCW Office of Research Standard Operating Procedure

MCW Office of Research Standard Operating Procedure MCW Office of Research Standard Operating Procedure USE AND STORAGE OF INVESTIGATIONAL DEVICES Unit: Applies to: Human Research Protections Program (HRPP), Office of Research MCW Faculty and Staff involved

More information

Sponsor/Investigator Responsibilities

Sponsor/Investigator Responsibilities Sponsor/Investigator Responsibilities Marian Serge, RN Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health Food and Drug Administration Marian.Serge@fda.hhs.gov

More information

The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement

The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption

More information

Introduction to the FDA. Historical Context. Changes over Time FDA - BE-200 9/23/2004. Copyright C. S. Tritt, Ph.D. 1

Introduction to the FDA. Historical Context. Changes over Time FDA - BE-200 9/23/2004. Copyright C. S. Tritt, Ph.D. 1 Introduction to the FDA C. S. Tritt, Ph.D. October 21, 2003 Historical Context In the early 1900 s people were being ripped off, made sick and even killed by bad food, patent medicines and cosmetics with

More information

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used) INVESTIGATIONAL DEVICE EXEMPTION APPLICATION IDE Title (if title being used) Name of Sponsor Investigator, MD X Professor, Department Icahn School of Medicine at Mount Sinai Date of Submission Form version

More information

Paths to Market & FDA Product Lifecycle Regulation. Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005

Paths to Market & FDA Product Lifecycle Regulation. Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005 Paths to Market & FDA Product Lifecycle Regulation Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005 FDA Organization U.S. Food & Drug Administration Headed by a Commissioner

More information

February 22, Dear Dr. Cox:

February 22, Dear Dr. Cox: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 Integra LifeSciences Corp.

More information

CBER Regulation of Devices for Cell Therapy

CBER Regulation of Devices for Cell Therapy CBER Regulation of Devices for Cell Therapy Richard D. McFarland, Ph.D., M.D. Associate Director for Policy Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and Research Food

More information

H-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS

H-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS H-20 Page 1 of 5 Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS PURPOSE: To describe the requirements for McLeod Health IRB review of Humanitarian Use Devices (HUD).

More information

Anatomy of an FDA Audit Trigger Prevention and Process

Anatomy of an FDA Audit Trigger Prevention and Process Robert S. Walsh, MD, MBA, FAHA, FCCP Walsh Medical Consulting 15 th Annual Product Complaints Congress Crystal City, VA 14 June 2017 How many here are from Pharma? Medical Device Industry? Biotechnology?

More information

Distinguishing Medical Device Recalls from Product Enhancements and Associated Reporting Requirements

Distinguishing Medical Device Recalls from Product Enhancements and Associated Reporting Requirements 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Distinguishing Medical Device Recalls from Product Enhancements and Associated Reporting Requirements Draft Guidance for Industry

More information

UT SOUTHWESTERN MEDICAL CENTER AT DALLAS INSTITUTIONAL REVIEW BOARD. Emergency Use of an Investigational Drug, Biologic or Device

UT SOUTHWESTERN MEDICAL CENTER AT DALLAS INSTITUTIONAL REVIEW BOARD. Emergency Use of an Investigational Drug, Biologic or Device Emergency Use of an Investigational Drug, Biologic or Device Introduction The emergency use provision in the FDA regulations (21 CFR 56.102d) is an exemption from prior review and approval by the IRB for

More information

Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist

Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist Agenda How an investigator should prepare and submit

More information

Sponsor-Investigator Responsibilities In Clinical Trials

Sponsor-Investigator Responsibilities In Clinical Trials In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.

More information

Glossary of Acronyms & FDA Regulations 2006 Dr. R. Don Green, Ph.D.

Glossary of Acronyms & FDA Regulations 2006 Dr. R. Don Green, Ph.D. 1 Glossary of Acronyms & FDA Regulations 2006 Dr. R. Don Green, Ph.D. drdg@prodigy.net 21 CFR Part 11 Electronic Records, Electronic Signatures 21 CFR Part 58 Current Good Laboratory Practice (CGLP) 21

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities

More information

January 3, AtriCure Inc. Melissa Smallwood Associate Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040

January 3, AtriCure Inc. Melissa Smallwood Associate Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service January 3, 2017 Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 AtriCure

More information

Evolving Regulatory Pathways for Medical Devices FDLI Annual Conference Access materials at fdli.org/annual2018

Evolving Regulatory Pathways for Medical Devices FDLI Annual Conference Access materials at fdli.org/annual2018 Evolving Regulatory Pathways for Medical Devices CDRH Policy Perspective/Key Initiatives CDRH 2018-2020 Strategic Priorities Simplicity & Collaborative Communities Implementing statutory changes, Cures

More information

AtriCure Inc. Jonathan McElwee Regulatory Affairs Manger 7555 Innovation Way Mason, Ohio 45040

AtriCure Inc. Jonathan McElwee Regulatory Affairs Manger 7555 Innovation Way Mason, Ohio 45040 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 AtriCure Inc. Jonathan

More information

Guidance on Requirements of the Sponsor and the Investigator as a Sponsor

Guidance on Requirements of the Sponsor and the Investigator as a Sponsor Guidance on Requirements of the Sponsor and the Investigator as a Sponsor University of Colorado Denver (UCD) secures assurances from the sponsor or the investigator-sponsor* that the manufacture and formulation

More information

1 The Clinical Research Coordinator (CRC)... 1

1 The Clinical Research Coordinator (CRC)... 1 TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...

More information

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Statutory Framework for Devices Medical Devices Investigational Use Application IDE (21 CFR 812) Abbreviated IDE Exempt Pre-Market Approval Applications 510(k) Pre-marketing Notification (21 CFR 807(e))

More information

ARE YOU READY? U.S. MEDICAL DEVICE REPORTING CODE TRANSITION

ARE YOU READY? U.S. MEDICAL DEVICE REPORTING CODE TRANSITION WHITE PAPER ARE YOU READY? U.S. MEDICAL DEVICE REPORTING CODE TRANSITION Authors: Kim Trautman and Mary Weick-Brady Researchers: Benny Gonzalez, Maria Monroy-Osorio and Jamie Zhu This white paper outlines

More information

COMBINATION PRODUCTS Inspection Readiness and Outcomes

COMBINATION PRODUCTS Inspection Readiness and Outcomes WHITE PAPER COMBINATION PRODUCTS Inspection Readiness and Outcomes Many companies think that because they have a good relationship with the FDA Center they interacted with during their submission reviews

More information

CGMP and Postmarketing Safety Reporting Requirements for Combination Products

CGMP and Postmarketing Safety Reporting Requirements for Combination Products CGMP and Postmarketing Safety Reporting Requirements for Combination Products GMP by the Sea August 29, 2017 Mark D. Kramer Regulatory Strategies, Inc. 1 Definition of a Combination Product A combination

More information

POLICY AND PROCEDURE MANUAL

POLICY AND PROCEDURE MANUAL POLICY AND PROCEDURE MANUAL PBRC: POLICY NO. 378.00 ORIGIN DATE: 5/25/2016 IMPACTS: CLINICAL RESEARCH LAST REVISED: 1/1/2017 SUBJECT: SOURCE: PURPOSE PENNINGTON BIOMEDICAL CLINICALTRIALS.GOV POLICY INSTITUTIONAL

More information

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,

More information

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug

More information

Streamlining IRB Procedures for Expanded Access

Streamlining IRB Procedures for Expanded Access Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs

More information

Using Benefit Risk in Making Post Market Decisions. Adam E Saltman MD PhD Medical Officer, FDA CDRH Office of Compliance AFDO 2018

Using Benefit Risk in Making Post Market Decisions. Adam E Saltman MD PhD Medical Officer, FDA CDRH Office of Compliance AFDO 2018 Using Benefit Risk in Making Post Market Decisions Adam E Saltman MD PhD Medical Officer, FDA CDRH Office of Compliance AFDO 2018 Objectives Understand why FDA is interested in the benefit-risk approach

More information

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the

More information

Summary Pediatric Device Stakeholders Meetings June 28, October 4 & 25, and November 1, 2004

Summary Pediatric Device Stakeholders Meetings June 28, October 4 & 25, and November 1, 2004 Summary Pediatric Device Stakeholders Meetings June 28, October 4 & 25, and November 1, 2004 In an ongoing effort to improve therapeutics and diagnostics for pediatric populations, the American Academy

More information

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework 1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health

More information

Managing Your Complaints and Obstacles in Post-Market Requirements -- Results from Top Medical Device Observations During an Inspection

Managing Your Complaints and Obstacles in Post-Market Requirements -- Results from Top Medical Device Observations During an Inspection Managing Your Complaints and Obstacles in Post-Market Requirements -- Results from Top Medical Device Observations During an Inspection *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER

More information

ELEMENTS OF A DATA MONITORING PLAN

ELEMENTS OF A DATA MONITORING PLAN ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and

More information

Course Materials You may duplicate this for each person attending the conference.

Course Materials You may duplicate this for each person attending the conference. TC001496A & Sharlin Consulting Course Materials You may duplicate this for each person attending the conference. Implementing the FDA Guidance on the Integrated Summary of Effectiveness by Joshua Sharlin,

More information

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory

More information

CDRH Pilot Activities

CDRH Pilot Activities CDRH Pilot Activities Cisco Vicenty Program Manager, Case for Quality 1 Office of Compliance, CDRH November 15, 2017 VCIP Voluntary Compliance Improvement Program Pilot Status Description: Assessment:

More information

Clinical Trials and Investigational Device Exemptions

Clinical Trials and Investigational Device Exemptions Clinical Trials and Investigational Device Exemptions Joshua Chetta, Ph.D. Investigational Device Exemption Program Clinical Trials Program Office of Device Evaluation Center for Devices and Radiological

More information

November 9, AtriCure, Inc. Jonathan McElwee Regulatory Affairs Manager 7555 Innovation Way Mason, Ohio 45040

November 9, AtriCure, Inc. Jonathan McElwee Regulatory Affairs Manager 7555 Innovation Way Mason, Ohio 45040 November 9, 2018 AtriCure, Inc. Jonathan McElwee Regulatory Affairs Manager 7555 Innovation Way Mason, Ohio 45040 Re: K182565 Trade/Device Name: AtriCure Regulation Number: 21 CFR 882.4250 Regulation Name:

More information

ORC Sponsor-Investigator IDE Checklist

ORC Sponsor-Investigator IDE Checklist A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA Code of Federal Regulations 21CFR812. This means that such investigators have additional responsibilities.

More information

Troubleshooting Informed Consent. Sandra Meadows, MPH, CIP Office of Responsible Research Practices June 26, 2018

Troubleshooting Informed Consent. Sandra Meadows, MPH, CIP Office of Responsible Research Practices June 26, 2018 Troubleshooting Informed Consent Sandra Meadows, MPH, CIP June 26, 2018 2 Session Objectives Identify common submission screening questions Examine IRB-required modifications related to the consent process

More information

SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES

SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES This policy applies to the following entity(s): Children s Hospital of Wisconsin Children s Hospital and Health System, Inc. Administrative Policy and Procedure Children s Research Institute SUBJECT: INSTITUTIONAL

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may

More information

Toward Greater Transparency and Rigor

Toward Greater Transparency and Rigor Toward Greater Transparency and Rigor TRANSPARENCY: ClinicalTrials.gov registration and results reporting The Center for Clinical & Translational Science 205.934.7442 ccts@uab.edu www.uab.edu/ccts @cctsnetwork

More information

ISPE Annual Meeting 29 October 1 November 2017 San Diego, CA

ISPE Annual Meeting 29 October 1 November 2017 San Diego, CA Post Marketing Safety Reporting (PMSR) Challenges and Successful Practices for Combination Products Objective Session Goals Summary of the final rule Interpretation for combination products approved as

More information

Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices

Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices Draft Guidance

More information

Medical Device Communiqué

Medical Device Communiqué Medical Device Communiqué Q2 2013 Demonstrating the Safety of Medical Devices in the Human Body 1 DOJ: The Focus is on GMPs in 2013 2 ROHS II Impacts Medical Device Companies 3 Demonstrating the Safety

More information

Medical Device Regulations

Medical Device Regulations Research Compliance Office Medical Device Regulations Jennifer S. Brown, RN IRB Education August 2008 Today s Topics AAHRPP FDA regulations Research categories Significant risk, NSR, IDE exempt IRB responsibilities

More information

Structure and Mandate of FDA

Structure and Mandate of FDA Structure and Mandate of FDA Leonard Sacks, M.D. Office of Medical Policy Center for Drug Evaluation and Research FDA FDA Clinical Investigator Training Course November 13, 2018 Mission of regulatory agencies

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional

More information

October 25, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

October 25, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers

More information

Overview of Biomarker Qualification. Marc K Walton MD, PhD Office of Translational Sciences CDER-FDA

Overview of Biomarker Qualification. Marc K Walton MD, PhD Office of Translational Sciences CDER-FDA Overview of Biomarker Qualification Marc K Walton MD, PhD Office of Translational Sciences CDER-FDA Categories of Biomarkers Prognostic Predictive Pharmacodynamic Including adverse response Efficacy-response

More information

Disclosures. Laboratory Stakeholders. IVD vs. LDT. FDA Regulation of Laboratory Developed Tests 10/2/2015. FDA Regulation of LDTs

Disclosures. Laboratory Stakeholders. IVD vs. LDT. FDA Regulation of Laboratory Developed Tests 10/2/2015. FDA Regulation of LDTs Disclosures FDA Regulation of Laboratory Developed Tests Beaumont Health System, 24 th Annual Symposium on Molecular Pathology September 16, 2015 Roger D. Klein, MD JD Director, Molecular Pathology Clinical

More information

FDA Inspections: FDA Inspections: An Overview Overview

FDA Inspections: FDA Inspections: An Overview Overview FDA Inspections: An Overview Robert Lindblad, MD The EMMES Corporation August 11, 2011 researchcartoons.com Why Inspections? Why Inspections? To evaluate compliance with regulations To establish that an

More information

De Novo Classification Process (Evaluation of Automatic Class III Designation) Guidance for Industry and Food and Drug Administration Staff

De Novo Classification Process (Evaluation of Automatic Class III Designation) Guidance for Industry and Food and Drug Administration Staff De Novo Classification Process (Evaluation of Automatic Class III Designation) Guidance for Industry and Food and Drug Administration Staff Document issued on October 30, 2017. The draft of this document

More information

SOP#: Original Approval Date: 3/25/13

SOP#: Original Approval Date: 3/25/13 STANDARD OPERATING PROCEDURE EXTERNAL SAFETY REPORTS - COOPERATIVE GROUP STUDIES SOP#: 6.2.5 Original Approval Date: 3/25/13 Version#: 1.0 Current Revision Date: n/a 1.0 PURPOSE/BACKGROUND The purpose

More information

Data Transparency and Quality Metrics

Data Transparency and Quality Metrics Data Transparency and Quality Metrics Ann Ferriter Division of Analysis and Program Operations Office of Compliance Center for Devices and Radiological Health Why are we interested in transparency? What

More information

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles

More information

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration FDA Perspective on MedDRA Coding Quality in Post marketing Safety Reports European Informal MedDRA User Group Webinar Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for

More information

Molecular Diagnostics: The Shift to Complexity. Molecular Diagnostics Regulation: Where do we go from here? David W Feigal, Jr.

Molecular Diagnostics: The Shift to Complexity. Molecular Diagnostics Regulation: Where do we go from here? David W Feigal, Jr. Molecular Diagnostics: The Shift to Complexity Molecular Diagnostics Regulation: Where do we go from here? David W Feigal, Jr., MD MPH April 17, 2015 Oversight of In Vitro Diagnostics States Center for

More information

Dan O Leary CBA, CQA, CQE, CRE, SSBB, CIRM President

Dan O Leary CBA, CQA, CQE, CRE, SSBB, CIRM President Unique Device Identification Dan O Leary CBA, CQA, CQE, CRE, SSBB, CIRM President Ombu Enterprises, LLC Dan@OmbuEnterprises.com www.ombuenterprises.com 603-209-0600 1 Outline Medical Device Regulation

More information

BIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective

BIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective BIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective Alan E. Williams, Ph.D. Office of Blood Research and Review Center for Biologics Evaluation and Research US Food and Drug Administration 15th International

More information

DEPARTMENT OF HEALTH & HUMAN SERVICES

DEPARTMENT OF HEALTH & HUMAN SERVICES DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -W066-G609 Silver Spring, MD 20993-0002 Lauren Baker, Ph.D. DEC

More information

Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order

Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order Document issued on: [Level 2, June 15, 2009] This guidance supersedes the document issued under this

More information

APEC GCP Inspection Workshop May 29, 2008

APEC GCP Inspection Workshop May 29, 2008 Common Investigator Deficiencies Jean Toth-Allen, Ph.D. APEC GCP Inspection Workshop May 29, 2008 Most Common CI Deficiencies Failure to follow the investigational plan Protocol deviations Inadequate recordkeeping

More information

Title: Review of Medical Devices Page: 1 of 5 Written by:

Title: Review of Medical Devices Page: 1 of 5 Written by: THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 031.1 Title: Review of Medical Devices Page: 1 of 5 Written by: Approved by: Laura W. Knight,

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Page 1 of 5 REVIEW OF INVESTIGATIONAL NEW DRUG (IND)/INVESTIGATIONAL DEVICE EXEMPTION (IDE) RESEARCH IN HUMAN SUBJECTS RESEARCH POLICY It is the policy of the University of Cincinnati that studies involving

More information

ATELIER RÈGLEMENTAIRE DM US/CANADA

ATELIER RÈGLEMENTAIRE DM US/CANADA ATELIER RÈGLEMENTAIRE DM US/CANADA February 19, 2014 Atlanpole Biotherapies 20 février 2014, Angers 2 Overview VCLS A team of seasoned healthcare product developers who advise on product development, and

More information

The Brave New World of Medical Devices

The Brave New World of Medical Devices The Brave New World of Medical Devices December 17, 2014 BOSTON GERMANY ISRAEL www.bmtadvisors.com www.bmtcrogroup.com 1 It Is All About The Adoption More Than a Mantra David Barone December 17, 2014 www.bmtadvisors.com

More information

May 22, Ranfac Corporation Mr. Christopher Whelan Senior Vice President 30 Doherty Avenue, P.O. Box 635 Avon, Massachusetts 02322

May 22, Ranfac Corporation Mr. Christopher Whelan Senior Vice President 30 Doherty Avenue, P.O. Box 635 Avon, Massachusetts 02322 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 Ranfac Corporation Mr.

More information

GUIDANCE FOR SPONSORS, INDUSTRY, RESEARCHERS, INVESTIGATORS, AND FOOD AND DRUG ADMINISTRATION STAFF

GUIDANCE FOR SPONSORS, INDUSTRY, RESEARCHERS, INVESTIGATORS, AND FOOD AND DRUG ADMINISTRATION STAFF GUIDANCE FOR SPONSORS, INDUSTRY, RESEARCHERS, INVESTIGATORS, AND FOOD AND DRUG ADMINISTRATION STAFF Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions:Compliance

More information

FDA Sponsor and Investigator Responsibility Checklist

FDA Sponsor and Investigator Responsibility Checklist FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator

More information

Question Yes No. 1. Is the study interventional (a clinical trial)? Study Type data element is Interventional

Question Yes No. 1. Is the study interventional (a clinical trial)? Study Type data element is Interventional Checklist for Evaluating Whether a Clinical Trial or Study is an Applicable Clinical Trial (ACT) Under 42 CFR 11.22(b) for Clinical Trials Initiated on or After January 18, 2017 1 (NOT FOR SUBMISSION 2

More information

Pharmacovigilance and the Generic Industry. Mark Vieder RPh MBA Director, Safety & Medical Writing Biorasi

Pharmacovigilance and the Generic Industry. Mark Vieder RPh MBA Director, Safety & Medical Writing Biorasi and the Generic Industry Mark Vieder RPh MBA Director, Safety & Medical Writing Biorasi Disclaimer: This presentation has been prepared by Biorasi, LLC solely for the purpose of sharing information and

More information

Conducted Under an IND to Support a

Conducted Under an IND to Support a Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.

More information

IRB APPLICATION OF FDA REGULATIONS Click for Animation

IRB APPLICATION OF FDA REGULATIONS Click for Animation IRB APPLICATION OF FDA REGULATIONS Click for Animation Created 12/2016 Belinda Smith & Jennifer Hill, University of Kentucky Office of Research Integrity Acknowledgement Ada Sue Selwitz FDA IRB Review

More information

A REVIEW OF MARKET ENTRY REQUIREMENTS FOR RISK MANAGEMENT, WITH SPECIAL EMPHASIS ON FDA AND ISO COMPLIANCE

A REVIEW OF MARKET ENTRY REQUIREMENTS FOR RISK MANAGEMENT, WITH SPECIAL EMPHASIS ON FDA AND ISO COMPLIANCE BYLINED ARTICLE ON: A REVIEW OF MARKET ENTRY REQUIREMENTS FOR RISK MANAGEMENT, WITH SPECIAL EMPHASIS ON FDA AND ISO 14971 COMPLIANCE By Mark Leimbeck PE Underwriters Laboratories and Larry Kessler Sc.D.

More information

November 18, Andersen Sterilizers, Inc. Dr. William Andersen President 3154 Caroline Drive Haw River, North Carolina 27258

November 18, Andersen Sterilizers, Inc. Dr. William Andersen President 3154 Caroline Drive Haw River, North Carolina 27258 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 November 18, 2015 Andersen

More information

Guidance for Clinical Investigators, Sponsors, and IRBs

Guidance for Clinical Investigators, Sponsors, and IRBs Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection u.s. Department of Health and Human Services Office of the Commissioner (OC) Center

More information

Off-Label Use Congress and FDA must balance: The need to regulate manufacturer promotion of off-label use of devices; and The need for and availabilit

Off-Label Use Congress and FDA must balance: The need to regulate manufacturer promotion of off-label use of devices; and The need for and availabilit Off-Label Use Versus Clinical Trial Use of Devices: FDA Regulatory Issues Neil F. O Flaherty Principal Olsson Frank Weeda Terman Bode Matz PC Off-Label Use Uses that do not appear in a device s FDA-approved

More information

510(k) Summary for the Tiger Cannulated Screw System

510(k) Summary for the Tiger Cannulated Screw System 510(k) Summary for the Tiger Cannulated Screw System In accordance with 21 CFR 807.92 of the Federal Code of Regulations the following 510(k) summary is submitted for the Tiger Cannulated Screw System.

More information

FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond

FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond Jeff Shuren, MD, JD Center for Devices and Radiological Health U.S. Food and Drug Administration May 4, 2017 1

More information

April 13, Background

April 13, Background Pfizer Inc 235 East 42nd Street New York, NY 10017-5755 Tel 212 733 4210 Fax 646 383 9249 Email: marc.wilenzick@pfizer.com April 13, 2009 http://www.regulations.gov Christine Ireland Committee management

More information

EVENT TYPE TIMING REQUIRED FORM

EVENT TYPE TIMING REQUIRED FORM Reportable Events EVENT TYPE TIMING REQUIRED FORM Unanticipated Problem or Adverse Event 10 days Event Reporting Form Death (related) 10 days Event Reporting Form Death (not related) Renewal Summary with

More information

Human Subjects Research: IRB Resources

Human Subjects Research: IRB Resources Research Compliance Office Human Subjects Research: IRB Resources Kristin B. Frazier HRPP Educational Specialist IRB Resources June 4, 2008 Topics Stanford Institutional Review Boards (IRB) Charge of IRB

More information

APR Dear Ms. Adair:

APR Dear Ms. Adair: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 APR 2 7 2004 Ms. Kaoru L. Adair Vice President Regulatory Affairs and

More information

MCW Office of Research Standard Operating Procedure

MCW Office of Research Standard Operating Procedure MCW Office of Research Standard Operating Procedure USE AND STORAGE OF INVESTIGATIONAL DRUGS AND BIOLOGICS Unit: Applies to: Human Research Protections Program (HRPP), Office of Research MCW/FH Faculty

More information

HUMANITARIAN USE DEVICES 3/8/2016

HUMANITARIAN USE DEVICES 3/8/2016 DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program HUMANITARIAN USE DEVICES 3/8/2016 It is the policy of the Duke University Health System Institutional Review Board (DUHS IRB) to review and

More information

FDA Decisions for Investigational Device Exemption (IDE) Clinical Investigations

FDA Decisions for Investigational Device Exemption (IDE) Clinical Investigations Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff FDA Decisions for Investigational Device Exemption (IDE) Clinical Investigations

More information

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH TITLE

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH TITLE SOP #: DATA-101 Page: 1 of 5 1. POLICY STATEMENT: Case Report Forms (CRFs) are designed by the Clinical Trials Research Informatics Office (CTRIO) in collaboration with the Sponsor, Overall PI, designated

More information

Expanded Access and the Individual Patient IND

Expanded Access and the Individual Patient IND Office of Regulatory Affairs and Quality Expanded Access and the Individual Patient IND Research Wednesdays July 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office

More information

FDA initiatives to facilitate evaluation of novel percutaneous valve technologies within the US

FDA initiatives to facilitate evaluation of novel percutaneous valve technologies within the US FDA initiatives to facilitate evaluation of novel percutaneous valve technologies within the US Nicole Ibrahim, PhD Chief, Structural Heart Devices Branch Division of Cardiovascular Devices ODE/CDRH/FDA

More information